Concave Supra-arch Branched Stent-Graft System for Treatment of Aortic Arch Diseases

Inclusion Criteria: 1. Patients who are ≥ 18 years old and ≤ 85 years old； 2. Patients with aortic arch diseases (involving aortic arch aneurysm, aortic dissection, aortic pseudoaneurysm, aortic ulcer, and intermural hematoma); 3. Anatomical criteria, including: 1. Ascending aorta length is greater than or equal to 50 mm (distance from aortic sinus to anterior edge of innominate artery); 2. The diameter range of the anchoring area at the proximal end of the main body is between 25-45 mm and the length is greater than or equal to 15 mm; 3. The diameter of the anchored area of the innominate artery is between 10-16 mm, the diameter of the anchored area of the left common carotid artery is between 5-12 mm, and the diameter of the anchored area of the left subclavian artery is between 5-12 mm. Anchorage zone length is greater than or equal to 15 mm; 4. Distance between the anterior edge of the innominate artery to the posterior edge of the left subclavian artery is less than or equal to 80 mm; 5. Have a suitable iliac, femoral, and superior arch arterial approach; 4. Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up visits as required by the protocol. Exclusion Criteria: 1. Patients with general or local infections that may increase the risk of endovascular graft infection; 2. Patients with severe stenosis, calcification, or mural thrombus in the stent anchoring area, which is likely to make the stent-graft difficult to adhere to or affect the patency of the stent; 3. Patients with neck vascular surgery within 3 months; 4. Patients with severe carotid or subclavian artery stenosis, calcification; 5. Patients with a history of acute coronary syndrome within 6 months: Acute coronary syndromes are cardiac acute ischemic syndromes resulting from rupture of an unstable atherosclerotic plaque in the coronary artery or erosion secondary to the formation of new blood 4 thrombus, including ST-elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina. 6. Patients with transient ischemic attack (TIA) or ischemic stroke within 3 months; 7. Patients with preoperative hepatic and renal dysfunction, \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeded the upper limit of normal level by a factor of five; Serum creatinine (Cr) \>150umol/L\]; 8. Patients with history of bleeding or coagulopathy, who cannot receive antiplatelet therapy; 9. Patients with severe aortic insufficiency or a history of prior aortic valve insufficiency treatment; 10. Patients with a history of hypersensitivity to contrast agents, anticoagulant antiplatelet agents, stents, delivery equipment materials (i.e., nitinol, polyester, PTFE, nylon polymer materials); 11. Patients with connective tissue diseases such as Marfan's syndrome, Egyptian syndrome, or Behcet's disease; 12. Patients with arteritis; 13. Patients with significant organ dysfunction or other serious disease; 14. Patients with life expectancy of not more than 1 year; 15. Patients who are not eligible for endovascular treatment per in the investigator's judgment of the investigator; 16. Women with planned pregnancy, pregnancy stage , or lactation 17. The patient participated in another clinical trial and was not out or withdrawn within the first 3 months of the screening period of this study.